|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davis A, Tinker AV and Friedlander M:
'Platinum resistant' ovarian cancer: What is it, who to treat and
how to measure benefit? Gynecol Oncol. 133:624–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coyle C, Cafferty FH, Vale C and Langley
RE: Metformin as an adjuvant treatment for cancer: A systematic
review and meta-analysis. Ann Oncol. 27:2184–2195. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dowling RJ, Niraula S, Chang MC, Done SJ,
Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ,
et al: Changes in insulin receptor signaling underlie neoadjuvant
metformin administration in breast cancer: A prospective window of
opportunity neoadjuvant study. Breast Cancer Res. 17:322015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar :
|
|
6
|
Blandino G, Valerio M, Cioce M, Mori F,
Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S,
et al: Metformin elicits anticancer effects through the sequential
modulation of DICER and c-MYC. Nat Commun. 3:8652012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sivalingam VN, Kitson S, McVey R, Roberts
C, Pemberton P, Gilmour K, Ali S, Renehan AG, Kitchener HC and
Crosbie EJ: Measuring the biological effect of presurgical
metformin treatment in endometrial cancer. Br J Cancer.
114:281–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Currie CJ, Poole CD, Jenkins-Jones S, Gale
EAM, Johnson JA and Morgan CL: Mortality after incident cancer in
people with and without type 2 diabetes: Impact of metformin on
survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Romero IL, McCormick A, McEwen KA, Park S,
Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of
type II diabetes and metformin use to ovarian cancer progression,
survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012.
View Article : Google Scholar
|
|
10
|
Kumar S, Meuter A, Thapa P, Langstraat C,
Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake
is associated with better survival in ovarian cancer: A
case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar
|
|
11
|
Jenkins Y, Sun TQ, Markovtsov V, Foretz M,
Li W, Nguyen H, Li Y, Pan A, Uy G, Gross L, et al: AMPK activation
through mitochondrial regulation results in increased substrate
oxidation and improved metabolic parameters in models of diabetes.
PLoS One. 8:e818702013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han G, Gong H, Wang Y, Guo S and Liu K:
AMPK/mTOR-mediated inhibition of survivin partly contributes to
metformin-induced apoptosis in human gastric cancer cell. Cancer
Biol Ther. 16:77–87. 2015. View Article : Google Scholar :
|
|
13
|
Ochoa-Gonzalez F, Cervantes-Villagrana AR,
Fernandez-Ruiz JC, Nava-Ramirez HS, Hernandez-Correa AC,
Enciso-Moreno JA and Castañeda-Delgado JE: Metformin induces cell
cycle arrest, reduced proliferation, wound healing impairment in
vivo and is associated to clinical outcomes in diabetic foot ulcer
patients. PLoS One. 11:e01509002016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Portela A and Esteller M: Epigenetic
modifications and human disease. Nat Biotechnol. 28:1057–1068.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan KM, Fang D, Gan H, Hashizume R, Yu C,
Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, et al: The
histone H3.3K27M mutation in pediatric glioma reprograms H3K27
methylation and gene expression. Genes Dev. 27:985–990. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng D, Kryczek I, Nagarsheth N, Zhao L,
Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al: Epigenetic
silencing of TH1-type chemokines shapes tumour immunity and
immunotherapy. Nature. 527:249–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chapman-Rothe N, Curry E, Zeller C, Liber
D, Stronach E, Gabra H, Ghaem-Maghami S and Brown R: Chromatin
H3K27me3/H3K4me3 histone marks define gene sets in high-grade
serous ovarian cancer that distinguish malignant, tumour-sustaining
and chemo-resistant ovarian tumour cells. Oncogene. 32:4586–4592.
2013. View Article : Google Scholar
|
|
19
|
Cao R and Zhang Y: The functions of
E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr
Opin Genet Dev. 14:155–164. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yi X, Guo J, Guo J, Sun S, Yang P, Wang J,
Li Y, Xie L, Cai J and Wang Z: EZH2-mediated epigenetic silencing
of TIMP2 promotes ovarian cancer migration and invasion. Sci Rep.
7:35682017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J,
Xiao L and Wang Z: Overexpression of EZH2 contributes to acquired
cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Cancer Biol Ther. 10:788–795. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Siddiqi FS, Majumder S, Thai K, Abdalla M,
Hu P, Advani SL, White KE, Bowskill BB, Guarna G, Dos Santos CC, et
al: The histone methyltransferase enzyme enhancer of zeste homolog
2 protects against podocyte oxidative stress and renal injury in
diabetes. J Am Soc Nephrol. 27:2021–2034. 2016. View Article : Google Scholar :
|
|
23
|
Gallagher KA, Joshi A, Carson WF, Schaller
M, Allen R, Mukerjee S, Kittan N, Feldman EL, Henke PK, Hogaboam C,
et al: Epigenetic changes in bone marrow progenitor cells influence
the inflammatory phenotype and alter wound healing in type 2
diabetes. Diabetes. 64:1420–1430. 2015. View Article : Google Scholar :
|
|
24
|
Litchfield LM, Mukherjee A, Eckert MA,
Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E and Romero IL:
Hyperglycemia-induced metabolic compensation inhibits metformin
sensitivity in ovarian cancer. Oncotarget. 6:23548–23560. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Wu L, Zhu J, Prokop LJ and Murad MH:
Pharmacologic therapy of diabetes and overall cancer risk and
mortality: A meta-analysis of 265 studies. Sci Rep. 5:101472015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gandini S, Puntoni M, Heckman-Stoddard BM,
Dunn BK, Ford L, DeCensi A and Szabo E: Metformin and cancer risk
and mortality: A systematic review and meta-analysis taking into
account biases and confounders. Cancer Prev Res (Phila). 7:867–885.
2014. View Article : Google Scholar
|
|
28
|
Zhang P, Li H, Tan X, Chen L and Wang S:
Association of metformin use with cancer incidence and mortality: A
meta-analysis. Cancer Epidemiol. 37:207–218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang ZJ and Li S: The prognostic value of
metformin for cancer patients with concurrent diabetes: A
systematic review and meta-analysis. Diabetes Obes Metab.
16:707–710. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moon HS, Kim B, Gwak H, Suh DH and Song
YS: Autophagy and protein kinase RNA-like endoplasmic reticulum
kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2α)
pathway protect ovarian cancer cells from metformin-induced
apoptosis. Mol Carcinog. 55:346–356. 2016. View Article : Google Scholar
|
|
31
|
Milewicz T, Kiałka M, Mrozińska S, Ociepka
A and Krzysiek J: Metformin - new treatment strategies for
gynecologic neoplasms. Przegl Lek. 70:81–84. 2013.In Polish.
|
|
32
|
Jara JA and López-Muñoz R: Metformin and
cancer: Between the bioenergetic disturbances and the antifolate
activity. Pharmacol Res. 101:102–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Menendez JA, Oliveras-Ferraros C, Cufí S,
Corominas-Faja B, Joven J, Martin-Castillo B and Vazquez-Martin A:
Metformin is synthetically lethal with glucose withdrawal in cancer
cells. Cell Cycle. 11:2782–2792. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bikas A, Jensen K, Patel A, Costello J Jr,
McDaniel D, Klubo-Gwiezdzinska J, Larin O, Hoperia V, Burman KD,
Boyle L, et al: Glucose-deprivation increases thyroid cancer cells
sensitivity to metformin. Endocr Relat Cancer. 22:919–932. 2015.
View Article : Google Scholar
|
|
35
|
Zhuang Y, Chan DK, Haugrud AB and
Miskimins WK: Mechanisms by which low glucose enhances the
cytotoxicity of metformin to cancer cells both in vitro and in
vivo. PLoS One. 9:e1084442014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS,
Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, et al: Metformin
inhibits cell proliferation, migration and invasion by attenuating
CSC function mediated by deregulating miRNAs in pancreatic cancer
cells. Cancer Prev Res (Phila). 5:355–364. 2012. View Article : Google Scholar
|
|
37
|
Cabello P, Pineda B, Tormo E, Lluch A and
Eroles P: The antitumor effect of metformin is mediated by miR-26a
in breast cancer. Int J Mol Sci. 17:12982016. View Article : Google Scholar :
|
|
38
|
Yu T, Wang C, Yang J, Guo Y, Wu Y and Li
X: Metformin inhibits SUV39H1-mediated migration of prostate cancer
cells. Oncogenesis. 6:e3242017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bonini MG and Gantner BN: The multifaceted
activities of AMPK in tumor progression - why the 'one size fits
all' definition does not fit at all? IUBMB Life. 65:889–896. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Demoinet E, Li S and Roy R: AMPK blocks
starvation-inducible transgenerational defects in Caenorhabditis
elegans. Proc Natl Acad Sci USA. 114:E2689–E2698. 2017. View Article : Google Scholar :
|
|
41
|
Sun X, Yang Q, Rogers CJ, Du M and Zhu MJ:
AMPK improves gut epithelial differentiation and barrier function
via regulating Cdx2 expression. Cell Death Differ. 24:819–831.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fu Y, Chen J, Pang B, Li C, Zhao J and
Shen K: EZH2-induced H3K27me3 is associated with epigenetic
repression of the ARHI tumor-suppressor gene in ovarian cancer.
Cell Biochem Biophys. 71:105–112. 2015. View Article : Google Scholar
|
|
43
|
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin
ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M, et al:
SUZ12 promotes human epithelial ovarian cancer by suppressing
apoptosis via silencing HRK. Mol Cancer Res. 10:1462–1472. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guo J, Cai J, Yu L, Tang H, Chen C and
Wang Z: EZH2 regulates expression of p57 and contributes to
progression of ovarian cancer in vitro and in vivo. Cancer Sci.
102:530–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao R, Cui T, Han C, Zhang X, He J,
Srivastava AK, Yu J, Wani AA and Wang QE: DDB2 modulates TGF-β
signal transduction in human ovarian cancer cells by downregulating
NEDD4L. Nucleic Acids Res. 43:7838–7849. 2015. View Article : Google Scholar :
|
|
46
|
Principe DR, Doll JA, Bauer J, Jung B,
Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β:
Duality of function between tumor prevention and carcinogenesis. J
Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar
|
